Approval · Notice of Compliance 38017 · 2026
PMS-TOFACITINIB: Notice of Compliance 38017
Issued July 30, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38017
- Date
- July 30, 2026
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Addition of a drug product manufacturing site and/or manufacturer involving production. Addition of a drug product manufacturing site and/or manufacturer involving primary packaging. Change in the drug product manufacturing process
- Canadian reference product
- XELJANZ (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PMS-TOFACITINIB | Not yet assigned | — |
Medicinal ingredients
- TOFACITINIB CITRATE 5 MG per TAB